arrow
M

Maria Summa

Istituto Italiano di Tecnologia
H指数:31
被引数:2,783

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Polypharmacology-Driven Approach to Alzheimer’s Disease and Tauopathies: Rational Design; Synthesis and Characterization of Amino-Pyrazole-Based Multikinase (GSK-3β/FYN-α/DYRK1A) Inhibitors

基于多靶点药物策略的阿尔茨海默病和tau蛋白病研究:氨基酸-吡唑类多靶点激酶(GSK-3β/FYN-α/DYRK1A)抑制剂的理性设计、合成与表征

2026-04-290
OA
Exposure of dams to Elexacaftor/ Tezacaftor/Ivacaftor during pregnancy and breastfeeding induces reversible alterations in newborn wild type CD-1 mice

孕期及哺乳期暴露于Elexacaftor/Tezacaftor/Ivacaftor可诱导野生型CD-1小鼠新生儿的可逆性改变。

2025-11-140
OAAI
Rational optimization of D3R/GSK-3β dual target-directed ligands as potential treatment for bipolar disorder: Design, synthesis, X-ray crystallography, molecular dynamics simulations, in vitro ADME, and in vivo pharmacokinetic studies

基于理性的D3R/GSK-3β双靶点导向配体的优化及其作为双相情感障碍潜在治疗药物的研究:设计、合成、X射线晶体学、分子动力学模拟、体外ADME及体内药代动力学研究

2025-06-250
PRE
Schiff Base-Based Hydrogel Embedded with In Situ Generated Silver Nanoparticles Capped by a Hyaluronic Acid-Diethylenetriamine Derivative for Wound Healing Application

席夫碱基水凝胶嵌入原位生成的银纳米粒子,透明质酸-二亚乙基三胺衍生物覆盖,用于伤口愈合

2024-04-116
PRE
Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer
2022-04-0113
OAAI
Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer (vol 39, 110641, 2022)
2022-04-011
OA
Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-Covalent N-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral Administration
2021-09-0114
OAAI